Moody’s assigns ‘Aa3’ rating to Memorial Sloan-Kettering Cancer Center’s bonds

Moody’s Investors Service has assigned an “Aa3” rating to up to $550 million of New York City-based Memorial Sloan-Kettering Cancer Center’s taxable, fixed rate series 2015 revenue bonds.

Advertisement

The rating assignment was supported by a number of factors, including MSKCC’s excellent market position and improved operating performance. The center ended the first nine months of fiscal 2014 with a 2.5 percent operating margin and a 12.3 operating cash flow margin.

MSKCC also faces some challenges, which were considered for the rating assignment, such as being involved in a period of capital investment.

The center’s outlook is stable, and according to Moody’s the outlook reflects the expectation “that the capital projects will open on-time and on-budget and that debt service coverage will improve as new revenue-generating facilities open.”

More articles on healthcare finance:

8 recent hospital, health system capital projects
8 recent hospital rating and outlook changes, affirmations
5 hospital CFOs in the headlines this week

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Financial Management

Advertisement

Comments are closed.